JP2022552152A5 - - Google Patents
Info
- Publication number
- JP2022552152A5 JP2022552152A5 JP2022520447A JP2022520447A JP2022552152A5 JP 2022552152 A5 JP2022552152 A5 JP 2022552152A5 JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022552152 A5 JP2022552152 A5 JP 2022552152A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- seq
- amino acid
- histidine
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025010928A JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909267P | 2019-10-02 | 2019-10-02 | |
| US62/909,267 | 2019-10-02 | ||
| PCT/US2020/054036 WO2021067775A1 (en) | 2019-10-02 | 2020-10-02 | Anto-connexin antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010928A Division JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022552152A JP2022552152A (ja) | 2022-12-15 |
| JP2022552152A5 true JP2022552152A5 (cg-RX-API-DMAC7.html) | 2023-10-10 |
| JP7805289B2 JP7805289B2 (ja) | 2026-01-23 |
Family
ID=75273959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520447A Active JP7805289B2 (ja) | 2019-10-02 | 2020-10-02 | 抗コネキシン抗体製剤 |
| JP2025010928A Pending JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010928A Pending JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12358981B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4037703A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7805289B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220113355A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114786719A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020358101A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156812A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067775A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| IL300245A (en) * | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
| CN115825201B (zh) * | 2022-07-28 | 2024-10-25 | 苏州凯劳生物科技有限公司 | 一种使用毛细管电泳仪电离还原蛋白二硫键并确定其自由巯基比例的方法 |
| WO2025199516A1 (en) * | 2024-03-22 | 2025-09-25 | Board Of Regents, The University Of Texas System | Compositions and methods for preserving or increasing lean muscle mass |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002362197A1 (en) | 2001-12-28 | 2003-07-24 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| PT2418220T (pt) | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| WO2005116236A2 (en) * | 2004-05-14 | 2005-12-08 | The Regents Of The University Of California | Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna |
| AU2009246640A1 (en) | 2008-05-15 | 2009-11-19 | Biogen Idec Ma Inc. | Anti-Fn14 antibodies and uses thereof |
| RU2408728C1 (ru) | 2009-07-28 | 2011-01-10 | Федеральное государственное учреждение "Государственный Научный Центр Социальной и Судебной Психиатрии им. В.П. Сербского" (ФГУ "ГНЦССП Росздрава") | Способ получения иммуногенного рекомбинантного экстраклеточного фрагмента коннексина-43 |
| KR101576174B1 (ko) | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
| RU2457862C1 (ru) | 2011-07-07 | 2012-08-10 | Федеральное государственное учреждение "Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения низкодифференцированных глиом |
| WO2015027120A1 (en) * | 2013-08-21 | 2015-02-26 | Jiang Jean X | Compositions and methods for targeting connexin hemichannels |
| CA2944330A1 (en) | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
| WO2016029191A2 (en) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
| AU2017224122B2 (en) | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN116854816A (zh) | 2018-04-02 | 2023-10-10 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| US11427639B2 (en) * | 2018-04-02 | 2022-08-30 | Richter Gedeon Nyrt. | Antibody-containing aqueous formulation and use thereof |
-
2020
- 2020-10-02 CA CA3156812A patent/CA3156812A1/en active Pending
- 2020-10-02 US US17/061,918 patent/US12358981B2/en active Active
- 2020-10-02 EP EP20872009.4A patent/EP4037703A4/en active Pending
- 2020-10-02 AU AU2020358101A patent/AU2020358101A1/en active Pending
- 2020-10-02 KR KR1020227014499A patent/KR20220113355A/ko active Pending
- 2020-10-02 CN CN202080082579.4A patent/CN114786719A/zh active Pending
- 2020-10-02 WO PCT/US2020/054036 patent/WO2021067775A1/en not_active Ceased
- 2020-10-02 JP JP2022520447A patent/JP7805289B2/ja active Active
-
2025
- 2025-01-24 JP JP2025010928A patent/JP2025061811A/ja active Pending
- 2025-06-11 US US19/235,455 patent/US20260049132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537316A5 (cg-RX-API-DMAC7.html) | ||
| TWI883117B (zh) | Tubulysin衍生物與細胞結合分子偶聯物的製劑配方 | |
| KR102603344B1 (ko) | 분지형 링커를 갖는 튜불리신 유사체의 접합체 | |
| JP2021512881A5 (cg-RX-API-DMAC7.html) | ||
| US11279924B2 (en) | Conditionally active polypeptides and methods of generating them | |
| EP2099489B1 (en) | Compositions and methods for treating a neoplasm | |
| ES3057518T3 (en) | Combination hbv therapy | |
| WO2020155017A1 (en) | A conjugate of an amanita toxin with branched linkers | |
| TWI853146B (zh) | 細胞結合分子與細胞毒性劑偶聯物 | |
| JP2020509031A5 (cg-RX-API-DMAC7.html) | ||
| KR20180064534A (ko) | 조건부 활성 폴리펩티드 | |
| RU2020112302A (ru) | Соединения для уменьшения вязкости биологических композиций | |
| CA3016172A1 (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
| JP2024506940A5 (cg-RX-API-DMAC7.html) | ||
| TW202003046A (zh) | 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法 | |
| FR2995214A1 (fr) | Solution a viscosite reduite de proteine a concentration elevee | |
| JP2021520393A5 (cg-RX-API-DMAC7.html) | ||
| EA200501131A1 (ru) | Парентеральные композиции пептидов для лечения системной красной волчанки | |
| CN116390943A (zh) | 工程化乙型肝炎病毒中和抗体和其用途 | |
| KR20240134971A (ko) | 나노바디-약물 부가물 및 그의 용도 | |
| JP2022519796A5 (cg-RX-API-DMAC7.html) | ||
| AR130041A1 (es) | Formulaciones de anticuerpos anti-tl1a | |
| JPWO2023008337A5 (cg-RX-API-DMAC7.html) | ||
| US20120315290A1 (en) | Inhibitors of ll-37 mediated immune reactivity to self nucleic acids | |
| US20110033448A1 (en) | Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids |